Aurobindo Pharma Limited has informed the Exchange regarding a press release dated August 04, 2025, titled "Press Release".
AUROPHARMA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Aurobindo Pharma reported Q1FY26 consolidated revenue of INR 7,868 Cr, up 4.0% year-on-year, driven by strong 18% growth in Europe (INR 2,338 Cr) and 55.2% growth in ARV (INR 355 Cr). US formulations revenue declined marginally by 1.9% to INR 3,488 Cr due to destocking and seasonal challenges, while API revenue fell 16.1% to INR 916 Cr. Net profit stood at INR 824 Cr, down 10.2% YoY, with EBITDA margin before forex/other income at 20.4%. The company received 14 final ANDA approvals from the USFDA during the quarter, taking cumulative approvals to 704, and launched 15 products. Basic & Diluted EPS came in at INR 14.20, and the board declared an interim dividend of INR 4.0 per share (400%) for FY25-26.
Mixed quarter for shareholders – topline growth was modest with margin pressure and a double-digit drop in net profit, though the interim dividend and robust Europe/ARV growth provide some support. The stock may react cautiously given the YoY profit decline, but strong ANDA pipeline (865 cumulative filings) signals long-term growth potential.